June 2013
Volume 54, Issue 15
ARVO Annual Meeting Abstract  |   June 2013
Intravitreal Dexamethasone Implant in Patients with Refractory Diabetic Macular Edema
Author Affiliations & Notes
  • Pietro Frascio
    Clinica Oculistica, Genova, Italy
  • Francesca Allavena
    Clinica Oculistica, Genova, Italy
  • Massimo Nicolò
    Clinica Oculistica, Genova, Italy
  • Serena Telani
    Clinica Oculistica, Genova, Italy
  • Carlo Traverso
    Clinica Oculistica, Genova, Italy
  • Footnotes
    Commercial Relationships Pietro Frascio, None; Francesca Allavena, None; Massimo Nicolò, None; Serena Telani, None; Carlo Traverso, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2386. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Pietro Frascio, Francesca Allavena, Massimo Nicolò, Serena Telani, Carlo Traverso; Intravitreal Dexamethasone Implant in Patients with Refractory Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2013;54(15):2386.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: To evaluate the effects of dexamethasone intravitreal implant in eyes with refractory diabetic macular edema (DME).

Methods: In this retrospective interventional study, 4 patients with decreased visual acuity, as a result of DME refractory to treatments with anti-VEGF and/or laser photocoagulation, received a dexamethasone intravitreal implant 0.7 mg. Main outcome measures included changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT).

Results: Six eyes of 4 patients (3 males, 1 female; mean age 70.7 years) were included in the analysis. The mean duration of DME was 36 months (range 24-48). All patients had undergone previous treatments for DME with intravitreal injections of anti-vascular endothelial growth factor, and/or laser photocoagulation before entering this study. At baseline, the mean BCVA was 0.73 logMAR, and the mean CRT was 475.2. The mean BCVA improved to 0.43 logMAR (p = 0.04), 0.41 logMAR (p = 0.04), 0.41 logMAR (p = 0.04), 0.53 logMAR (p = 0.1), 0.41 logMAR (p = 0.04) and 0.53 logMAR (p = 0.1) at 1, 2, 3, 6, 9 and 12 months of follow-up respectively. The mean CRT improved to 361.5 (p=0.003), 322.7 (p =0.004), 326.0 (p = 0.02), 349.5 (p = 0.01), 312.8 (p=0.002)and 314.3 (p=0.02) after 1, 2, 3, 6, 9 and 12 months of follow-up respectively. Two eyes were retreated at month 6 and 1 eye at month 9. One eye developed a transient intraocular pressure (IOP) increase 1 month after injection, which was successfully managed with topical IOP-lowering medication.

Conclusions: Our data show that in eyes with refractory DME, a dexamethasone intravitreal implant produced a statistically significant improvement in BCVA and CRT and may represent a novel therapeutic option.

Keywords: 499 diabetic retinopathy • 505 edema  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.